ICG-MAL Application in tumor diagnosis and therapy Indocyanine Green ICG-Maleimide ICG-Maleimide CAS 2143933-81-5

The application of ICG-MAL in tumor diagnosis and treatment is mainly achieved by targeting molecules on the surface of tumors (e.g., tumor antigens, tumor cell surface receptors, etc.), and specific applications include the following:

1. Early tumor diagnosis: ICG-MAL can bind to tumor-associated molecules to achieve highly specific diagnosis of tumors. For example, researchers used ICG-MAL-labeled anti-HER2 monoclonal antibody (trastuzumab) to perform fluorescence microscopy imaging of HER2-positive breast cancer, and found that ICG-MAL-labeled antibody was able to clearly show the location and number of HER2-positive tumor cells, realizing highly sensitive diagnosis of early breast cancer.

2. Tumor therapy monitoring: ICG-MAL can be used to assess the efficacy and progress of tumor therapy. For example, researchers injected ICG-MAL-labeled anti-PD-L1 monoclonal antibody into mice and observed the changes in tumor PD-L1 expression through fluorescence microscopy imaging, and found that the level of tumor PD-L1 expression decreased after immunotherapy, proving that ICG-MAL can be used as a monitoring tool for the effect of tumor treatment.

3. Tumor surgery guidance: ICG-MAL can be used as a fluorescent guidance agent to help surgeons accurately locate and remove tumors. For example, researchers injected ICG-MAL-labeled octreotide into a patient's neuroendocrine tumor and guided the surgery through fluorescence microscope imaging, successfully removing the tumor and preserving normal tissues, avoiding unnecessary damage in the surgery.

In summary, ICG-MAL has a wide range of application prospects in tumor diagnosis and treatment, and is expected to become an important tool in tumor therapy.